GAVRETO Safety

GAVRETO offers a well-established safety profile

Thyroid patient safety

Safety of GAVRETO was evaluated in 138 patients with RET-altered thyroid cancer1*

*Includes 19 patients with RET fusion-positive thyroid cancer.

RET+=rearranged during transfection.

Adverse reactions (≥15%) in RET-altered thyroid cancer patients who received GAVRETO in ARROW1

Adverse ReactionsGAVRETO (N=138)*
Grades 1-4 (%)Grades 3-4 (%)
Musculoskeletal
Musculoskeletal pain420.7
Gastrointestinal
Constipation410.7
Diarrhea345
Abdominal pain170.7
Dry mouth170
Stomatitis170.7
Nausea170.7
Vascular
Hypertension4021
General
Fatigue386
Edema290
Pyrexia222.2
Respiratory
Cough271.4
Dyspnea222.2
Nervous system
Headache240
Peripheral neuropathy200
Dizziness190.7
Dysgeusia170
Skin and subcutaneous
Rash240
Metabolism and nutrition
Decreased appetite150

*Includes 19 patients with RET fusion-positive thyroid cancer.
For grouped terms, please refer to the U.S. Prescribing Information (USPI).
Only includes a Grade 3 adverse reaction.

Clinically relevant adverse reactions in <15% of patients who received GAVRETO included tumor lysis syndrome and increased creatine phosphokinase.

Dose reductions, interruptions, and discontinuations due to adverse reactions while taking GAVRETO1,2

  • 3.6% discontinued due to adverse reactions considered treatment-related by the trial investigator2
  • 9% of patients permanently discontinued GAVRETO due to any adverse reaction1
  • 44% of patients treated experienced dose reductions due to an adverse reaction1
  • 67% of patients treated experienced dosage interruptions due to an adverse reaction1

Select laboratory abnormalities (≥20%) worsening from baseline in patients who received GAVRETO in ARROW1

Laboratory Abnormality§GAVRETO (N=138)*
Grades 1-4 (%)Grades 3-4 (%)
Chemistry
Decreased calcium (corrected)709
Increased aspartate aminotransferase (AST)694.3
Increased alanine aminotransferase (ALT)433.6
Increased creatinine410
Decreased albumin411.5
Decreased sodium282.2
Decreased phosphate288
Decreased magnesium270.7
Increased potassium261.4
Increased bilirubin241.4
Increased alkaline phosphatase221.4
Hematology
Decreased lymphocytes6727
Decreased hemoglobin6313
Decreased neutrophils5916
Decreased platelets312.9
GAVRETO showed Grades 3-4 AST/ALT elevations of 4.3% and 3.6%.1

*Includes 19 patients with RET fusion-positive thyroid cancer.
§Denominator for each laboratory parameter is based on the number of patients with a baseline and post-treatment laboratory value available, which ranged from 135 to 138 patients.

Other clinically relevant laboratory abnormalities in patients who received GAVRETO included increased phosphate (40%).1

Recommended Dose Modifications
When should I modify dosage?

View the recommended dose reductions for GAVRETO for adverse reactions.

GAV_THR-25011 0525

References:

 

1. GAVRETO® [Package insert], South San Francisco, CA: Rigel Pharmaceuticals, Inc.

 

2. GAVRETO: Data on file, Rigel Pharmaceuticals, Inc. June 2024.